CYduct Diagnostics Inc (CYDX)

[blueskies]

Stick around....things might just get exciting.

What lead us here - SNDY

Solos Endoscopy completed the Stage 1 Audit with TUV SUD America on Tuesday, February 26, 2013.

June 12, 2013 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company and TUV SUD America has scheduled its Stage 2 ISO 13485 Audit for August 16, 2013.

Solos Endoscopy obtaining the CE Mark on its MammoView® devices to sell the MammoView® in the European Union. ISO 13485:2003 certification is also a necessary for the company to sell the MammoView® product line in Canada.

Oct 8, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce that the Company has passed its Stage 2 audit with Notified Body and registrar TÜV SÜD for registration to ISO 13485:2003. The Stage 2 audit was conducted August 15 - 16, 2013. TÜV SÜD found no non-conformities to Solos Endoscopy's Quality Management System requirements in the audit.

"Solos Endoscopy is committed to the worldwide distribution of its endoscopic instruments. We believe this dedication will result in increased sales and profits for the Company and its shareholders," stated Robert Segersten, Solos Endoscopy, CEO.

Solos Endoscopy retained Emergo Europe to act as the official Authorized Representative in Europe. Emergo will provide Solos assistance related to communications with authorities and importation of Solos instruments in Europe

Nov 7, 2013 - Solos Endoscopy, Inc. (OTC Pink: SNDY) is pleased to announce its new MammoView® Breast Cancer Global Initiative for 2014. Solos Endoscopy plans to work with various breast cancer awareness campaigns year round to continue building upon the public's "brand awareness" for breast cancer; its detection, its treatment, and the need for a reliable, permanent cure.

Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014.

Jan 10, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY) a provider of quality innovative healthcare instruments to Hospitals across the Country, posted an update for the shareholders on OTC Markets.com.

Solos Endoscopy completed the Audit with TUV SUD America this past year, which included a comprehensive review of the Solos Endoscopy's Quality Manual and 28 Quality System Procedures for compliance with the international quality system standard ISO 13485:2003, to the European Union's Medical Device Directive (MDD 93/42/EEC) and to the Canadian Medical Device Regulations (SOR/98-282). Since the completion of the Audit, the Company has been in contact with the representatives from both TUV SUD and Expert Resources and expects to be certified to ISO 13485:2003 in the next few weeks. Certification to ISO 13485:2003 will in turn allow Solos Endoscopy to obtain the CE Mark on the majority of endoscopic instruments including the MammoView® devices.

Solos has several exciting new advances in product development that will change the way minimally invasive procedures are utilized in the medical field in order to treat and prevent disease

Jan 28, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the country, is pleased to announce that the Company has received its ISO 13485:2003 Certification from TUV SUD America.

"ISO Certification is an amazing accomplishment for a company our size. I am proud to say that Solos Endoscopy now carries endoscopic instruments that are both FDA approved and ISO Certified," stated Robert Segersten, President of Solos Endoscopy.

Now that Solos Endoscopy is ISO Certified, the Company will begin to focus its sales efforts internationally

Feb 20, 2014 - Solos Endoscopy, Inc. (OTC Pink: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that the company has commenced negotiations with a Canadian distributor to sell its endoscopic instruments including the MammoView® devices in Canada.

The Certification Body of TUV America has certified that Solos Endoscopy has established and is maintaining a quality management system that meets the requirements of the European Union and Canada.

April 30, 2014 - The Company is currently in discussions with Spectrum Medical Market Consultants to act as its regulatory consultant in Canada for its endoscopic instruments including the MammoView® devices.

July 18, 2014 – Presidents Letter - http://www.otcmarkets.com/financialReportViewer?symbol=SNDY&id=123610

Nov 12, 2014 (eTeligis.com via COMTEX) -- BOSTON, MA, United States, via ETELIGIS INC., 11/12/2014 - - BOSTON, MA /ETELIGIS/ Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to Hospitals across the Country, is pleased to announce that the company's MamoView(R) Breast Endoscopy System has shown strong growth over the past 18 months

"Management expects sales of the MamoView(R) to increase in the future as more physicians are trained in the procedure," stated Robert Segersten, President of Solos Endoscopy.

Nov 24, 2014 -- BOSTON, MA, United States, via ETELIGIS INC., 11/24/2014 - - Solos Endoscopy, Inc. (OTC Pink: SNDY) (PINKSHEETS: SNDY), a provider of quality innovative healthcare instruments to hospitals across the United States, is pleased to announce that it has been invited to participate at the 8th International Dr. Susan Love Research Foundation Symposium on the Breast.

Blueskies

SNDY